GGrantIndex
Sort

21,453 grants matching tuberculosis

RP3: Targeting ATG gene-dependent immunity for novel anti-infective therapeutics

$1,177,671
Seungmin Hwang · Ut Southwestern Medical Center · U19 · FY2021 · AI

Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts

$1,177,109
Timothy R Sterling · Vanderbilt University Medical Center · R01 · FY2022 · AI

COLUMBIA-ADARC AIDS CLINICAL TRIALS UNIT

$1,176,475
Columbia University Health Sciences · U01 · FY2000 · AI

TUBERCULOSIS CONTROL AND ELIMINATION IN THE CITY OF CHICAGO

$1,176,285
Kathleen A Ritger · Chicago Department Of Public Health · U52 · FY2014 · PS

Tuberculosis Surveillance, Prevention and Control, and Laboratory Upgrade

$1,174,948
Maureen E Murphy · Ohio State Department Of Health · U52 · FY2011 · PS

Infectiousness and social mixing in asymptomatic TB as a driver of population-level transmission

$1,173,748
Nippie Sarita Shah · Emory University · R01 · FY2025 · AI

Chemically Modified Peptide Nucleic Acids

$1,173,550
Daniel H Appella · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK

Immune Regulation in Mycobacterial and Fungal Infections

$1,173,111
Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

PS05-003 TUBERCULOSIS ELIMINATION AND LABORATORY

$1,172,939
Angelito Bravo · Arizona State Department Of Hlth Srvcs · U52 · FY2008 · PS

Chemical Biological Discovery of Lipid Virulence Factors in the Major Bacterial Pathogens

$1,172,914
David Branch Moody · Brigham And Women'S Hospital · R01 · FY2025 · AI

Predicting immune responses that correlate with protection against tuberculosis

$1,172,751
Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2013 · HL

Development and Support of the Pathway Tools Software

$1,172,505
Peter D Karp · Sri International · R01 · FY2021 · AI

PS05-003 TUBERCULOSIS ELIMINATION AND LABORATORY

$1,171,614
Angelito Bravo · Arizona State Department Of Hlth Srvcs · U52 · FY2009 · PS

Adjuvant Development in the context of a vaccine to protect against tuberculosis

$1,170,507
Nikolai Petrovsky · Vaxine Pty Ltd · N01 · FY2021 · AI

Development and Support of the Pathway Tools Software

$1,170,230
Peter D Karp · Sri International · R01 · FY2022 · AI

Tuberculosis Elimination

$1,169,106
Jon Warkentin · Tennessee State Department Of Health · U52 · FY2015 · PS

Genes And Gene Products As Immunoadjuvants

$1,168,549
Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)

$1,167,864
Payam Nahid · University Of California, San Francisco · R01 · FY2014 · AI

TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENT

$1,167,406
Mary McIntyre · Alabama State Dept Of Public Health · U52 · FY2015 · PS

Miami Treatment and Prevention Clinical Trials Unit (CTU)

$1,166,422
Margaret A Fischl · University Of Miami School Of Medicine · UM1 · FY2017 · AI

Immunoregulation /Immune Recognition In Filarial/Nonfilarial Parasitic Infection

$1,165,642
Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

Production of Pedigreed SPF Rhesus Macaques

$1,164,674
Jeffrey A Roberts · University Of California At Davis · U42 · FY2020 · OD

Kaiser Washington Vaccine and Treatment Evaluation Unit

$1,164,520
Lisa A Jackson · Kaiser Foundation Research Institute · UM1 · FY2021 · AI

Systems Biology

$1,164,123
Rafick-Pierre Sekaly · Beth Israel Deaconess Medical Center · U19 · FY2012 · AI

Task A12 Small Animal Models for Testing of Products Against Mycobacteria

$1,163,838
· N01 · FY2010 · AI